Biotech Values

[DewDiligence]

BOCX—Comical update from another biotech scam I first posted about seven years ago:

http://finance.yahoo.com/news/BioCurex-Updates-Its-pz-3811842527.html?x=0&.v=2

Although this is our near term focus, BioCurex is not just a cancer diagnostic company. While we have concentrated our efforts on blood tests for cancer detection, our technology is broadly based on the existence of a molecule we named RECAF that is present in cancer cells but practically absent from healthy cells.

Thus, we can use RECAF for diagnostic purposes and we can also use RECAF to image tumors and selectively target them for destruction. Tumors can be imaged using radioactive isotopes or targeted for killing with toxins or poisons that hone on RECAF and destroy RECAF bearing cancer cells without damaging normal cells that lack RECAF. This should ameliorate the unwanted side effects of chemotherapy.

ABT was once interested in what BOCX calls RECAF, but they dumped it a few years ago. Back to the pump from BOCX’s CEO:

BioCurex China is established in Shanghai, within a facility dedicated to manufacturing rapid tests for the Chinese market… This provides us with access to the technology and the know-how required to develop and manufacture rapid tests for both human and canines. We achieve the best results when the intensity of the reaction is assessed with a small (hand-held) instrument similar to the ones used by diabetic patients to measure their blood glucose rather than visually. Our associates in Shanghai have developed an inexpensive reader for rapid tests and they are adapting our rapid test to work with that hand-held reader. The market impact of having an inexpensive reader with a rapid test that can be performed at the vet's clinic in real time cannot be stressed enough.

LOL—no scam biotech company worth its salt fails to mention the bright prospects for its products in China.